The University of Michigan Comprehensive Cancer Center (UMCCC) Prostate SPORE Administration Cores responsible for leadership, guidance and management. The Administration Core oversees all aspects andperforms numerous duties across the expansive scope of the SPORE. These duties are to: i) providescientific leadership to SPORE investigators; 2) direct the translational components of the overall SPOREprogram; 3) function as the coordinating unit for SPORE activities and information; 4) oversee andadminister all budgetary issues and finances; 5) maintain UMCCC Prostate SPORE web page; 6) provideadministrative framework for all projects, research development, career development, and cores; 7)administer the yearly competition for pilot projects and seed grants; 8) apply cost effectiveness and qualitycontrol factors; 9) facilitate interactions between the SPORE and the University, 10) facilitate interactionsbetween the SPORE and other SPOREs and the NCI; 11) communicate with NCI program staff andcoordinate submission of required reports; 12) convene and provide administrative support for meetings; 13)Drovide oversight for the recruitment of women and minorities; 14) assure compliance with regulationsregarding animals in research; and 15) coordinate quality assurance between tissue banks and databases.Kenneth J. Pienta, MD, co-director of urologic oncology for the University of Michigan ComprehensiveCancer Center continues to serve as principal investigator of the Administrative Core. Kathleen Cooney, MD,continues to serve as a co-director of the Administrative Core. Dr. Cooney oversees all of the developmentalprograms as well as the Biostatistics and Tissue Cores. James Montie, M.D., continues to serve as a codirectorresponsible for the translational science of the SPORE through his direction of the ClinicalApplications Committee. Ms. Jill Miller has filled the role as SPORE administrator since 1998 and willcontinue in this role. She has demonstrated her ability to administer this large research program in anefficient manner. This core provides the framework to support the success and mission of the UMCCCSPORE as a cohesive group of investigators committed to the development of translational research inprostate cancer.The success of the translational mission of this project and the SPORE was exemplified this year by ourintegrated team of investigators working together and utilizing SPORE resources to win the 1st annual AACRTeam Science Award for the discovery of the importance of the TMPRSS:ETS family gene fusions inprostate cancer tumorigenesis. This Award was established by the American Association for CancerResearch (AACR) to acknowledge and catalyze the growing importance of interdisciplinary teams to theunderstanding of cancer and/or the translation of research discoveries into clinical cancer applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA069568-11
Application #
7468647
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Project Start
2008-06-01
Project End
2013-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
11
Fiscal Year
2008
Total Cost
$269,656
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Rye, Morten Beck; Bertilsson, Helena; Andersen, Maria K et al. (2018) Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized. BMC Cancer 18:478
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Singhal, Udit; Wang, Yugang; Henderson, James et al. (2018) Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res 16:643-654
Wang, Xiaoju; Qiao, Yuanyuan; Asangani, Irfan A et al. (2017) Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. Cancer Cell 31:532-548.e7
Blattner, Mirjam; Liu, Deli; Robinson, Brian D et al. (2017) SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell 31:436-451
Dai, Xiangpeng; Gan, Wenjian; Li, Xiaoning et al. (2017) Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med 23:1063-1071
Lin, Ke-Chih; Torga, Gonzalo; Wu, Amy et al. (2017) Epithelial and mesenchymal prostate cancer cell population dynamics on a complex drug landscape. Converg Sci Phys Oncol 3:
Piert, Morand; Montgomery, Jeffrey; Kunju, Lakshmi Priya et al. (2016) 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies. J Nucl Med 57:1065-70
Van Allen, Eliezer M; Robinson, Dan; Morrissey, Colm et al. (2016) A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. Oncotarget 7:52888-52899
Mehra, Rohit; Udager, Aaron M; Ahearn, Thomas U et al. (2016) Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. Eur Urol 70:549-552

Showing the most recent 10 out of 527 publications